2025年,肝细胞癌的系统治疗的发展格局在2025年
Karan Kumar1, Vivek A Saraswat1
1Department of Hepatology and Liver Transplantation, Mahatma Gandhi University of Medical Sciences and Technology, Jaipur, India.
晚期肝细胞癌 (HCC) 的全身治疗正在发展. 新的向疗法和免疫疗法提供了创新的治疗选择,改善了肝癌患者的治疗结果.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 肝细胞癌 (HCC) 是一种常见的恶性瘤,通常在晚期诊断,需要全身治疗.
- 了解瘤分子通路和瘤微环境推动了HCC治疗的创新.
研究的目的:
- 审查先进的HCC系统治疗的最新进展.
- 突出新型治疗策略和药物组合的潜力.
主要方法:
- 审查目前的全身疗法,包括氨酸激酶抑制剂 (TKI),VEGF抑制剂和免疫疗法.
- 对具有里程碑意义的临床试验结果进行分析,探索针对HCC的创新策略和药物组合.
主要成果:
- 向疗法 (例如,伦瓦提尼布,索拉芬尼布) 和免疫疗法 (例如,阿特佐利祖马布-贝瓦西祖马布) 在治疗晚期HCC方面表现出有效性.
- 针对性疗法和免疫疗法的组合正在显示出显著的临床益处.
结论:
- 晚期HCC的治疗环境正在迅速发展,新的全身疗法正在迅速发展.
- 这些创新有望实现更有效,个性化的治疗方案和改善患者的治疗结果.
更多相关视频
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
08:25Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma
Published on: April 25, 2025
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Hepatic Portal System
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
